BTIG Maintains Buy on Caris Life Sciences, Lowers Price Target to $32

Benzinga Newsdesk www.benzinga.com Negative 50.3%

Neg 50.3% Neu 0% Pos 0%

BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $38 to $32.